课题基金 / 基金详情

CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT

CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT
血红素衍生抗凝剂的表征
批准号:
3345351
负责人:
ROBERT L JONES
金额:
$11.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-30 至 1988-09-29

项目摘要

项目成果

ROBERT L JONES的其他基金

相似基金

相关文献

中文摘要
翻译
本提案中描述的项目旨在定义 血红素衍生的生化、生物学和药理学意义 抗凝剂(HDA)。 HDA 可延长体外凝血时间 和体内。 HDA 是产生的衍生物或降解产物 当血红素静置在溶液中或将其注入 老鼠。 HDA将在体外和体内被纯化和鉴定 来源通过色谱和光谱技术。 这将测试 HDA 是血红素(血红素)的单一衍生物的假设 能够与凝血蛋白相互作用产生深远的影响 功能效果。 HDA与特定物质的相互作用机制 纤维蛋白原、凝血酶和因子 VIII:C 的蛋白质定义为 确定结合亲和力和对酶功能的影响 天然和合成底物。 紫外-可见分光光度计的具体技术 光谱学、平衡透析和与铁结合的拮抗作用 化合物将检验涉及铁或微量金属的假设 HDA 与凝血蛋白的相互作用。 生产和 HDA 体内机制将通过分离的肝血红素来确定 代谢系统和整个动物。 这将检验以下假设: HDA是血红素的代谢产物,其机制与 在体外看到的。 具体技术涉及放射性同位素和 药理学探针。 最后,HDA 的药理潜力将是 通过使用放射性标记的药代动力学和功效研究确定 HDA 和各种给药途径。 完成这些研究将 定义 HDA 的生化、生理和药理学意义。
英文摘要
The project described in this proposal is designed to define the biochemical, biologic and pharmacologic significance of hematin-derived anticoagulant (HDA). HDA produces prolongation of clotting times in vitro and in vivo. HDA is a derivative or degradation product which is produced when hematin is allowed to stand in solution or when it is infused into rats. HDA will be purified and identified from in vitro and in vivo sources by chromatographic and spectroscopic techniques. This will test the hypothesis that HDA is a single derivative of hematin (heme) which is capable of interacting with coagulation proteins to produce profound functional effects. The mechanism of interaction of HDA with the specific proteins fibrinogen, thrombin and factor VIII:C will be defined by determining binding affinities and effects on enzymatic function with natural and synthetic substrates. The specific techniques of UV-Vis spectroscopy, equilibrium dialysis and antagonism with iron binding compounds will test the hypothesis that iron or a trace metal is involved in the interaction of HDA with clotting proteins. The production and mechanism of HDA in vivo will be defined with isolated hepatic heme metabolic systems and whole animals. This will test the hypothesis that HDA is a metabolic product of heme and that the mechanism is identical to that seen in vitro. Specific techniques involve radioisotope and pharmacologic probes. Finally, the pharmacologic potential of HDA will be determined by pharmacokinetic and efficacy studies utilizing radiolabelled HDA and various routes of administration. Completion of these studies will define the biochemical, physiologic and pharmacologic significance of HDA.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers.
正常志愿者静脉注射血红素后出现血栓性静脉炎和止血障碍。
DOI: 10.1016/s0002-9343(88)80092-5
发表时间: 1988
期刊: The American journal of medicine
影响因子: --
作者: [Simionatto,CS, Cabal,R, Jones,RL, Galbraith,RA]
通讯作者: Galbraith,RA
GRANTS FOR PREDOCTORAL TRAINING IN FAMILY MEDICINE
CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT
  • 批准号:
    3345348
  • 项目类别:
  • 资助金额:
    $11.22万
  • 财政年份:
    1985
  • 负责人:
    ROBERT L JONES
  • 依托单位:
CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT
  • 批准号:
    3345346
  • 项目类别:
  • 资助金额:
    $7.12万
  • 财政年份:
    1985
  • 负责人:
    ROBERT L JONES
  • 依托单位:
CHARACTERIZATION OF HEMATIN DERIVED ANTICOAGULANT
  • 批准号:
    3345350
  • 项目类别:
  • 资助金额:
    $1.15万
  • 财政年份:
    1985
  • 负责人:
    ROBERT L JONES
  • 依托单位:
海外基金